Oncodesign Precision Med... 주식 가격. ALOPM - 주식 시세, 차트, 과거 거래, 주식 채팅, 재무.

실시간 스트리밍 인용문, 아이디어 및 실시간 토론을 위한 허브

프리미엄

가격

0.42

매수가

0.35

매도가

0.43

거래량

18,010

0.37 일간 변동폭 0.43

0.33 52주 범위 1.68

market_cap

7.64M

전일 종가

0.384

개장가

0.37

최근 거래 시간

128

0.42

마지막 거래 시간

재정 규모

VWAP

평균 볼륨(3m)

15,682

발행 주식

18,190,878

배당수익률

주가수익률

-0.94

주당순이익(EPS)

-0.44

매출

1.08M

순이익

-8.09M

섹터

Electromedical Apparatus

산업

Electromedical Apparatus

웹사이트

www.oncodesign.com

본부

Dijon, Cote-d'or, Fra

설립됨

Oncodesign Precision Medicine SA is listed in the Electromedical Apparatus sector of the 유로넥스트 (Euronext) with ticker ALOPM. The last closing price for Oncodesign Precision Med... was 0.38 €. Over the last year, Oncodesign Precision Med... shares have traded in a share price range of 0.33 € to 1.68 €.

Oncodesign Precision Med... currently has 18,190,878 shares in issue. The market capitalisation of Oncodesign Precision Med... is 6.99 € million. Oncodesign Precision Med... has a price to earnings ratio (PE ratio) of -0.94.

Oncodesign Precision Medicine : Bilan semestriel du contrat de liquidité confié à la société TP ICAP (Europe)

Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN : FR001400CM63 ; Mnémonique : ALOPM), entreprise biopharmaceutique spécialisée en...

Oncodesign Precision Medicine reprend les droits sur son programme OPM-201 auprès de Servier après une phase I volontaires sains positive

Reprise par OPM de l’intégralité des droits du programme OPM-201 et du portefeuille de brevets associé Confirmation de l’innocuité de la...

OPM détaille les résultats finaux de son étude de phase 1 avec OPM-101, inhibiteur de la cible RIPK2, avec des données de sécurité solides sans toxicité cardiaque, ouvrant la voie au lancement de la phase 1b/2a

Finalisation du rapport d’étude de l’essai de phase 1 de l’OPM-101 contrôlé par placebo en double aveugle chez 104 volontaires sains (VS) ayant...

OPM Announces Poster Presentation on OPM-101, a RIPK2 Kinase Inhibitor, in Healthy Volunteers at UEG Week 2024 Conference

Presentation by Professor Laurent Peyrin-Biroulet (M.D., PhD Professor of Gastroenterology at CHRU of Nancy) and Bruno Robin (PharmD, Head of OPM...

OPM annonce ses résultats du premier semestre 2024 et fait le point sur ses développements cliniques, et sa situation financière

OPM-101 conclut positivement sa Phase 1 volontaires sains permettant de prévoir le démarrage d'un essai clinique de Phase 1b/2a, fin 2024 début...

OPM annonce les résultats positifs de la phase 1 volontaires sains d’OPM-101 : engagement significatif de la cible avec un excellent profil de sécurité

Fin de l’essai de phase 1 avec OPM-101 contrôlé par placebo et en double aveugle : 104 volontaires sains (VS) ont participé à cet essai visant à...

기간	변동	변동 %	시가	고가	저가	평균 일일 거래량	VWAP
1	-0.04	-8.69565217391	0.46	0.46	0.33	24115	0.38822523	DE
4	-0.17	-28.813559322	0.59	0.616	0.33	22415	0.45684825	DE
12	-0.63	-60	1.05	1.055	0.33	15682	0.61376115	DE
26	-0.71	-62.8318584071	1.13	1.38	0.33	11915	0.84564376	DE
52	-0.865	-67.3151750973	1.285	1.68	0.33	11199	1.03220792	DE
156	-0.57	-57.5757575758	0.99	2.39	0.33	11026	1.35511358	DE
260	-0.57	-57.5757575758	0.99	2.39	0.33	11026	1.35511358	DE

ALOPM - Frequently Asked Questions (FAQ)

What is the current Oncodesign Precision Med... share price?

The current share price of Oncodesign Precision Med... is 0.42 €

How many Oncodesign Precision Med... shares are in issue?

Oncodesign Precision Med... has 18,190,878 shares in issue

What is the market cap of Oncodesign Precision Med...?

The market capitalisation of Oncodesign Precision Med... is EUR 6.99M

What is the 1 year trading range for Oncodesign Precision Med... share price?

Oncodesign Precision Med... has traded in the range of 0.33 € to 1.68 € during the past year

What is the PE ratio of Oncodesign Precision Med...?

The price to earnings ratio of Oncodesign Precision Med... is -0.94

What is the cash to sales ratio of Oncodesign Precision Med...?

The cash to sales ratio of Oncodesign Precision Med... is 7.08

What is the reporting currency for Oncodesign Precision Med...?

Oncodesign Precision Med... reports financial results in EUR

What is the latest annual turnover for Oncodesign Precision Med...?

The latest annual turnover of Oncodesign Precision Med... is EUR 1.08M

What is the latest annual profit for Oncodesign Precision Med...?

The latest annual profit of Oncodesign Precision Med... is EUR -8.09M

What is the registered address of Oncodesign Precision Med...?

The registered address for Oncodesign Precision Med... is 18 RUE JEAN MAZEN, DIJON, COTE-D'OR, 21000

What is the Oncodesign Precision Med... website address?

The website address for Oncodesign Precision Med... is www.oncodesign.com

Which industry sector does Oncodesign Precision Med... operate in?

Oncodesign Precision Med... operates in the ELECTROMEDICAL APPARATUS sector

가장 활성
% 상승자
% 패자

기호	가격	볼륨
ALADOAdomos	0.59 € (180.95%)	162.85k
ALCYBCybergun	0.0002 € (100.00%)	24.87M
DMSBSDiagnostic Medical Systems	0.008 € (77.78%)	50k
ALAMAAMA Corporation PLC	0.233 € (29.81%)	847.73k
LUDSLucibel DS	0.0015 € (25.00%)	13.29k
NEGDSNetmedia Group DS	0.0001 € (-50.00%)	698
ALPCVCerinnov Group	0.618 € (-33.55%)	230.29k
ALKALKALRAY SA	0.641 € (-27.98%)	530.33k
BPOSTBpost SA NV	1.522 € (-26.83%)	6.5M
FRVIAForvia SE	8.442 € (-22.62%)	6.19M
ATOAtos SE	0.0032 € (0.00%)	472.41M
BCPBanco Comercial Portugues SA	0.5366 € (-4.89%)	135.45M
BIOSBiosenic	0.0029 € (-6.45%)	37.45M
ALALOAcheterLouerFR	0.0073 € (0.00%)	36.35M
ALVERVergnet	0.0004 € (0.00%)	33.19M

JamesLH 14 분 전

The SEC investigation is active and quite alive, unlike your FAKE subpoenas and police reports, LMFAO. If Nick Scampanella was keeping up with his bills and not deliquent on his NJ mailbox, he would have known the SEC is actively looking for him. But this scammer is hiding, as evident by his complet

SNPW

janice shell 25 분 전

Listening to Trumpty today, or any day, you'd think we were the only country in the world that's helped Ukraine with military stuff since 2022. That's very, very far from the truth. A remarkable number of countries have contributed in various ways. As to the lies Trump's repeatedly told about Europe

DJPele 27 분 전

"Middle of the week"

Well, see you in a month when you make another prediction out of thin air 👋🏽

NWBO

manibiotech 29 분 전

You mean out of 100s of millions of shares she bought with hard earned post tax money ?
Ok thanks

NWBO

MrMike241 30 분 전

Nope, I make judgments based on the source. Trump is everywhere. What he says is what matters. Same for all. I'm not a lemming, are you?

Understand that the reason I post here is singular. In spite of everything happening, my primary concern is protecting the constitution of the Unite

real777mellon 34 분 전

Ours are even more special - that's probably why the feature asset protection, and that exempt list I just found. Lots of reasons why they would put such accounts at Chase Manhattan Bank, N.A. for our property trustee and the account. Wouldn't want to put that account where something was not 100% su

LEHNQ

quester614 38 분 전

WHY does XERI show a different amount for R&D expense at the end of June 2021 compared to the XTI amount if this represents JV funding??
How is the additional R&D money separated into a different classification from the amount of R&D money spent on the JV as CLAIMED by the XTI filing?????????

XERI

littlejohn 42 분 전

putin is genocide promoter that Ukraine

can't afford to trust...

Vance is considered anti-Ukraine and

shouldn't have been in the meeting...

A U.S. Gov't running huge deficits that is

laying off folks and can't afford to fund

janice shell 44 분 전

Legacy media is dead. Mainstream media is dead.

It's all podcasts and social media memes.

The younger generation doesn't care about CNN

It's definitely a new beginning for USA.

Or perhaps a definitive end. Yes, those young people are just b

thecrusher2011 44 분 전

Every single one of you is dangerously misinformed by the liberal media.

It's amazing how little truth you all have been given.

"Ukraine was eventually forced to accept the Budapest Memorandum without robust security guarantees under pressure from the U.S. and Russia, i

toohot 50 분 전

BIEL up 50% at Friday’s close.
‘Nuff said!

BUY $BIEL$

BIEL

Woodpile42 52 분 전

I hope that’s not the case…

VXIT

Investor2014 52 분 전

To me it seems clear!
I agree the speed of which a trial can be executed is very important.
The only new trial recently is the suck it and see one with A3-71.

I can't help thinking that Missling is stringing out new trials with A2-73 until there are some assurances that

AVXL

Jimmy Joe 53 분 전

Probably using it as a tax write off. Complete scam so far.

JPEX

Jimmy Joe 55 분 전

Sucks investors in leaves them with their pants around their ankles.

Known spoofer.

GME

littlejohn 57 분 전

Oil price selloff looking akey fakey now...

https://apnews.com/article/zelenskyy-security-guarantees-trump-meeting-washington-eebdf97b663c2cdc9e51fa346b09591d

Oil stocks that are so beaten down

didn't know about this little change...

Ukrain

GVInvestments 1 시간 전

Everyone that I talk to now hate elon. tesla is headed staright to bankcruptcy

TSLA

Jimmy Joe 1 시간 전

Already saw Denaro's video.

Hey, do whatcha gotta do. You tend to contradict yourself all the time. Tired~? Sell.

$AMC baby~!

AMC

fuagf 1 시간 전

That's the day i'm flying out, the Australian date day, i mean .. ;-)

fuagf 1 시간 전

Probably shouldn't have said likely.... just one of those feeeeelingssss .. lol

fuagf 1 시간 전

Yeah, it was great, just tangented me is all...

janice shell 1 시간 전

lol, 31 March. I just missed being an April Fool.

시장 데이터

뉴스

도구

시장

팔로우

Hot Features

피드 팔로우

실시간 옵션 플로우

모니터

Oncodesign Precision Medicine SA (ALOPM)

실시간 스트리밍 인용문, 아이디어 및 실시간 토론을 위한 허브

주요 통계 및 세부정보

Oncodesign Precision Medicine SA 정보

ALOPM 최신 뉴스

Oncodesign Precision Medicine : Bilan semestriel du contrat de liquidité confié à la société TP ICAP (Europe)

Oncodesign Precision Medicine reprend les droits sur son programme OPM-201 auprès de Servier après une phase I volontaires sains positive

OPM détaille les résultats finaux de son étude de phase 1 avec OPM-101, inhibiteur de la cible RIPK2, avec des données de sécurité solides sans toxicité cardiaque, ouvrant la voie au lancement de la phase 1b/2a

OPM Announces Poster Presentation on OPM-101, a RIPK2 Kinase Inhibitor, in Healthy Volunteers at UEG Week 2024 Conference

OPM annonce ses résultats du premier semestre 2024 et fait le point sur ses développements cliniques, et sa situation financière

OPM annonce les résultats positifs de la phase 1 volontaires sains d’OPM-101 : engagement significatif de la cible avec un excellent profil de sécurité

Oncodesign Precision Medicine : Bilan semestriel du contrat de liquidité confié à la société TP ICAP (Europe)

Oncodesign Precision Medicine reprend les droits sur son programme OPM-201 auprès de Servier après une phase I volontaires sains positive

OPM Reports Final Results of Its Phase 1 Study With RIPK2 Inhibitor OPM-101, With Strong Safety Data and No Cardiac Toxicity, Paving the Way for the Launch of Phase 1b/2a

OPM annonce la présentation d’un poster sur OPM-101, inhibiteur de la kinase RIPK2, chez les volontaires sains lors du congrès de l’UEG Week 2024

OPM annonce ses résultats du premier semestre 2024 et fait le point sur ses développements cliniques, et sa situation financière

OPM annonce les résultats positifs de la phase 1 volontaires sains d’OPM-101 : engagement significatif de la cible avec un excellent profil de sécurité

Oncodesign Precision Medicine : Bilan semestriel du contrat de liquidité confié à la société TP ICAP (Europe)

Oncodesign Precision Medicine : Apport complémentaire au contrat de liquidité

OPM met à disposition les informations relatives à l’Assemblée Générale des actionnaires du 26 juin 2024

ALOPM - Frequently Asked Questions (FAQ)

이동자

토론

최근 히스토리

회사 소개

사업

Popular

앱 받기

시장 데이터

뉴스

도구

시장

팔로우

Hot Features

피드 팔로우

실시간 옵션 플로우

모니터

Oncodesign Precision Medicine SA (ALOPM) 시세

Oncodesign Precision Medicine SA (ALOPM)

실시간 스트리밍 인용문, 아이디어 및 실시간 토론을 위한 허브

주요 통계 및 세부정보

Oncodesign Precision Medicine SA 정보

ALOPM 최신 뉴스

Oncodesign Precision Medicine : Bilan semestriel du contrat de liquidité confié à la société TP ICAP (Europe)

Oncodesign Precision Medicine reprend les droits sur son programme OPM-201 auprès de Servier après une phase I volontaires sains positive

OPM détaille les résultats finaux de son étude de phase 1 avec OPM-101, inhibiteur de la cible RIPK2, avec des données de sécurité solides sans toxicité cardiaque, ouvrant la voie au lancement de la phase 1b/2a

OPM Announces Poster Presentation on OPM-101, a RIPK2 Kinase Inhibitor, in Healthy Volunteers at UEG Week 2024 Conference

OPM annonce ses résultats du premier semestre 2024 et fait le point sur ses développements cliniques, et sa situation financière

OPM annonce les résultats positifs de la phase 1 volontaires sains d’OPM-101 : engagement significatif de la cible avec un excellent profil de sécurité

Oncodesign Precision Medicine : Bilan semestriel du contrat de liquidité confié à la société TP ICAP (Europe)

Oncodesign Precision Medicine reprend les droits sur son programme OPM-201 auprès de Servier après une phase I volontaires sains positive

OPM Reports Final Results of Its Phase 1 Study With RIPK2 Inhibitor OPM-101, With Strong Safety Data and No Cardiac Toxicity, Paving the Way for the Launch of Phase 1b/2a

OPM annonce la présentation d’un poster sur OPM-101, inhibiteur de la kinase RIPK2, chez les volontaires sains lors du congrès de l’UEG Week 2024

OPM annonce ses résultats du premier semestre 2024 et fait le point sur ses développements cliniques, et sa situation financière

OPM annonce les résultats positifs de la phase 1 volontaires sains d’OPM-101 : engagement significatif de la cible avec un excellent profil de sécurité

Oncodesign Precision Medicine : Bilan semestriel du contrat de liquidité confié à la société TP ICAP (Europe)

Oncodesign Precision Medicine : Apport complémentaire au contrat de liquidité

OPM met à disposition les informations relatives à l’Assemblée Générale des actionnaires du 26 juin 2024

ALOPM - Frequently Asked Questions (FAQ)

이동자

토론

최근 히스토리

회사 소개

사업

Popular

앱 받기

광고 제거